This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Sep 25, 2026
•
3 min read
🧬 Lundbeck to relocate U.S. headquarters to Boston, establishing global innovation hub to expand neuroscience and AI capabilities, Merck & Co., Eisai's Welireg (belzutifan)-Lenvima (lenvatinib) combo wins FDA approval for second-line clear cell renal cell carcinoma after Ph3, Genentech, Earendil Labs partner on AI-driven cancer bispecific antibodies, $55M upfront, $1.5B+ deal
Sep 24, 2026
🧬 FDA approves Eli Lilly's Onswik (insulin efsitora alfa-gobe) for type 2 diabetes in Ph3-backed once-weekly insulin, Eli Lilly, InnoCare Pharma partner on five unmet need targets, $100M upfront, $3.25B milestones, Merck & Co.'s (remigromig) meets primary endpoint in Ph2b/3 trial for diabetic macular edema, Wnt pathway agonist shows noninferiority
Sep 23, 2026
🧬 AstraZeneca's Trixeo (budesonide/glycopyrronium/formoterol fumarate dihydrate) gains EU approval for asthma following Ph3 success, Boehringer Ingelheim expands Variant Bio cardiovascular collaboration, adding $250M in potential milestones, Roche, Ionis Pharmaceuticals' (sefaxersen) meets Ph3 endpoint in primary immunoglobulin A nephropathy, supporting accelerated approval bid
Sep 22, 2026
4 min read
🧬 Boehringer Ingelheim, Envisagenics sign $1B multi-year oncology collaboration leveraging AI RNA splicing platform SpliceCore, J&J's Caplyta (lumateperone) meets Ph3 primary endpoint in bipolar I disorder-associated manic episodes, Iambic Therapeutics files for IPO, advancing AI-driven HER2 inhibitor IAM1363 for solid tumors
Sep 21, 2026
🧬 Telix to acquire ITM for up to $2.35B, aiming to build radiopharmaceutical powerhouse, Ultragenyx wins FDA approval for Fayuvi (rebisufligene etisparvovec), first-ever gene therapy for Sanfilippo syndrome type A, China unveils five-year plan targeting 25% of global innovative drug approvals by 2030
Sep 17, 2026
🧬 Bayer's Kerendia (finerenone) wins third FDA approval for chronic kidney disease associated with type 1 diabetes, Novo, Orbis Medicines partner on oral macrocycle cardiometabolic therapies, up to $1.4B in milestones, Lisata Therapeutics merges with Marea Therapeutics in reverse merger, raising $225M after failed Kuva Labs acquisition
Sep 16, 2026
🧬 Novartis acquires Sironax's blood-brain barrier delivery platform for $125M, Sling Therapeutics raises $123M Series C to advance oral thyroid eye disease treatment, Circle Pharma raises $92.5M Series E to advance cyclin D1 inhibitor for breast cancer
Sep 15, 2026
🧬 GSK acquires Chimagen Biosciences' trispecific T cell engager for multiple myeloma, deal worth up to $750M, FDA approves Curium's Bexlutry (lutetium Lu 177 dotatate), first radioligand equivalent targeting somatostatin receptor for gastroenteropancreatic neuroendocrine tumors, Electra Therapeutics plans $325M IPO to fund late-stage sHLH trial
Sep 14, 2026
🧬 Scholar Rock's Isembyld (apitegromab) wins FDA approval for spinal muscular atrophy following Ph3 success, Novo Nordisk rebrands to Novo, repositions amid GLP-1 market struggles against Eli Lilly, GSK, Hansoh Pharmaceutical's (risvutatug rezetecan) cuts death risk 54% in Ph3 relapsed small-cell lung cancer trial
Sep 12, 2026
7 min read
[Republished Feature] Grove Biopharma uses protein-like polymers to deliver peptides inside cells, opening the door to drug targets that have long been considered unreachable.
Sep 11, 2026
🧬 Handa Oncology receives FDA final approval for Omcazio (cabozantinib) across multiple oncology indications including renal cell carcinoma, EnterpriseSG launches Boston biotech hub in Kendall Square, targeting life sciences partnerships with Massachusetts firms, Argonaut Manufacturing Services divests life sciences, diagnostics unit to 1315 Capital, forming Aluris Sciences
Sep 10, 2026
🧬 FDA expands Bayer's Hyrnuo (zipalertinib) approval to first-line HER2-mutant non-small cell lung cancer via Ph1/2 data, Frazier Life Sciences nets $1.1B for public fund targeting small, mid-cap biotechs, CordenPharma expands aseptic fill-finish capacity to 500 million sterile injectable units annually with €80M ($93.1M) investment
